Published in Cancer on January 15, 2002
Radiofrequency Ablation of Painful Soft Tissue Neoplasms | NCT00041886
Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv (2010) 1.32
Current treatment for liver metastases from colorectal cancer. World J Gastroenterol (2003) 1.28
Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One (2013) 1.14
Radiofrequence ablation of liver cancers. World J Gastroenterol (2002) 1.08
Remote thermometry to avoid complications in radiofrequency ablation. J Vasc Interv Radiol (2003) 1.05
Respiratory motion compensation with tracked internal and external sensors during CT-guided procedures. Comput Aided Surg (2006) 1.02
Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future. World J Hepatol (2011) 0.95
Radiofrequency ablation for cancer-associated pain. J Pain (2002) 0.95
Image fusion using CT, MRI and PET for treatment planning, navigation and follow up in percutaneous RFA. Exp Oncol (2009) 0.94
Accuracy and efficacy of percutaneous biopsy and ablation using robotic assistance under computed tomography guidance: a phantom study. Eur Radiol (2013) 0.92
Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. J Control Release (2012) 0.90
Reduction of peak acoustic pressure and shaping of heated region by use of multifoci sonications in MR-guided high-intensity focused ultrasound mediated mild hyperthermia. Med Phys (2013) 0.89
Optical Fibre Pressure Sensors in Medical Applications. Sensors (Basel) (2015) 0.88
CT-guided radiofrequency ablation of pediatric Wilms tumor in a solitary kidney. Pediatr Radiol (2005) 0.88
Experimental study on the feasibility and safety of radiofrequency ablation for secondary splenomagely and hypersplenism. World J Gastroenterol (2003) 0.84
Fiber-optic chirped FBG for distributed thermal monitoring of ex-vivo radiofrequency ablation of liver. Biomed Opt Express (2014) 0.82
Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG. Oncoscience (2014) 0.81
Iodine quantification with dual-energy CT: phantom study and preliminary experience with VX2 residual tumour in rabbits after radiofrequency ablation. Br J Radiol (2013) 0.80
Perk Station--Percutaneous surgery training and performance measurement platform. Comput Med Imaging Graph (2009) 0.78
Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses. Can Urol Assoc J (2009) 0.78
Radiofrequency ablation of primary and metastatic lung tumors: preliminary experience with a single center device. Surg Endosc (2006) 0.77
Evolving technology in bipolar perfused radiofrequency ablation: assessment of efficacy, predictability and safety in a pig liver model. Eur Radiol (2006) 0.76
Evaluation of a tissue-mimicking thermochromic phantom for radiofrequency ablation. Med Phys (2016) 0.75
Feasibility of percutaneous excision followed by ablation for local control in breast cancer. Ann Surg Oncol (2011) 0.75
Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep (2016) 0.75
A comprehensive review of pulsed radiofrequency in the treatment of pain associated with different spinal conditions. Br J Radiol (2017) 0.75
Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg (1999) 5.25
Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology (1999) 4.99
Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol (2000) 4.14
Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment. J Bone Joint Surg Am (1998) 3.56
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol (2001) 2.67
Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol (2000) 2.62
Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics (2000) 2.59
Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg (1999) 2.40
Hepatic ablation using radiofrequency electrocautery. Invest Radiol (1990) 2.38
Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am (2006) 2.32
Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip electrodes. Radiology (1997) 2.27
Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol (1998) 2.23
Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg (1998) 2.19
Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol (1998) 2.17
Radio-frequency ablation of renal cell carcinoma: early clinical experience. Radiology (2000) 2.15
Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastases. Radiology (1997) 2.15
Pathologic analysis of photothermal and photomechanical effects of laser-tissue interactions. Photochem Photobiol (1991) 1.98
Radiofrequency tissue ablation: increased lesion diameter with a perfusion electrode. Acad Radiol (1996) 1.89
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Radiofrequency ablation of breast cancer: first report of an emerging technology. Arch Surg (1999) 1.68
Neurosurgery for trigeminal neuralgia: comparison of alcohol block, neurectomy, and radiofrequency coagulation. Clin J Pain (1996) 1.58
Imaging-guided percutaneous biopsy of focal splenic lesions: update on safety and effectiveness. AJR Am J Roentgenol (1999) 1.42
Treatment of colorectal liver metastases. Br J Surg (1999) 1.41
Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg (1999) 1.39
Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol (1997) 1.34
Percutaneous radiofrequency tissue ablation: optimization of pulsed-radiofrequency technique to increase coagulation necrosis. J Vasc Interv Radiol (1999) 1.33
A cooled needle electrode for radiofrequency tissue ablation: thermodynamic aspects of improved performance compared with conventional needle design. Acad Radiol (1996) 1.31
Radio frequency ablation of renal cell carcinoma via image guided needle electrodes. J Urol (1999) 1.29
Radio-frequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. Radiology (1998) 1.27
Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg (1998) 1.24
Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol (1998) 1.21
Tissue ablation with radiofrequency using multiprobe arrays. Acad Radiol (1995) 1.21
Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst (2001) 1.19
Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg (2000) 1.18
Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med (1999) 1.16
Controlled thermal injury of bone. Report of a percutaneous technique using radiofrequency electrode and generator. Invest Radiol (1989) 1.07
Ex vivo experiment on radiofrequency liver ablation with saline infusion through a screw-tip cannulated electrode. J Surg Res (1997) 1.06
Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage (1998) 1.00
Hepatic cryoablation, but not radiofrequency ablation, results in lung inflammation. Ann Surg (2000) 0.99
Interventional radiology in the spleen. Radiology (1986) 0.99
New applications of ultrasonography: interventional ultrasound. Eur J Radiol (1998) 0.97
Enhanced radiofrequency ablation of canine prostate utilizing a liquid conductor: the virtual electrode. J Endourol (1996) 0.97
Percutaneous treatment of hepatic neoplasms: A review of current techniques. Cardiovasc Intervent Radiol (1998) 0.94
Laparoscopic ablation of liver adenoma by radiofrequency electrocauthery. Gastrointest Endosc (1995) 0.92
Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. Urology (1997) 0.87
How to use cytodiagnostic spleen puncture. Acta Med Scand (1976) 0.86
Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection. J Surg Oncol (1998) 0.85
Radiofrequency ablation of metastatic lesions in adrenocortical cancer. Ann Intern Med (2000) 0.83
Percutaneous imaging-guided biopsy of the spleen. AJR Am J Roentgenol (1999) 0.83
Radiofrequency thermal ablation of a splenic metastasis. J Vasc Interv Radiol (2001) 0.83
New trends in the surgical treatment of colorectal cancer liver metastases. Tumori (1998) 0.79
Radiofrequency ablation in surgery. Surg Technol Int (1997) 0.77
Liver tumor ablation techniques. J Invest Surg (1997) 0.77
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol (2013) 4.25
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol (2011) 2.61
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther (2002) 1.88
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist (2008) 1.85
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol (2009) 1.70
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab (2003) 1.70
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A (2002) 1.64
Adjuvant mitotane for adrenocortical cancer--a recurring controversy. J Clin Endocrinol Metab (2008) 1.55
Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer (2008) 1.54
Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg (2011) 1.54
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A (2003) 1.53
Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem (2005) 1.52
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer (2010) 1.51
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. J Natl Cancer Inst (2011) 1.50
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. Cancer Biol Ther (2002) 1.48
Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res (2004) 1.45
Thermal protection during percutaneous thermal ablation of renal cell carcinoma. J Vasc Interv Radiol (2004) 1.42
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol (2005) 1.41
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer (2003) 1.36
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol (2013) 1.32
Hereditary renal cancers. Radiology (2003) 1.31
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol (2003) 1.27
Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst (2008) 1.27
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res (2004) 1.23
Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol (2008) 1.21
Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol (2004) 1.20
Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J (2009) 1.19
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res (2007) 1.19
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res (2006) 1.18
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res (2005) 1.16
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res (2009) 1.15
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist (2008) 1.14
The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs (2004) 1.12
Partial adrenalectomy: the National Cancer Institute experience. Urology (2005) 1.12
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res (2003) 1.12
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res (2003) 1.11
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer (2005) 1.10
Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 1.07
Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol (2011) 1.05
False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer (2012) 1.05
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res (2010) 1.04
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res (2004) 1.02
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry (2004) 1.02
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol (2009) 1.01
Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg (2008) 0.98
Characterization of gene rearrangements leading to activation of MDR-1. J Biol Chem (2006) 0.98
The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU Int (2005) 0.98
Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology (2002) 0.98
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther (2002) 0.97
A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res (2010) 0.96
Management of von Hippel-Lindau-associated kidney cancer. Nat Clin Pract Urol (2005) 0.95
Intraoperative ultrasound aids in dissection during laparoscopic partial adrenalectomy. J Urol (2002) 0.93
Radiofrequency ablation for tumor-related massive hematuria. J Vasc Interv Radiol (2005) 0.93
Laparoscopic management of extra-adrenal pheochromocytoma. J Urol (2004) 0.93
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood (2002) 0.93
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. Mutat Res (2005) 0.92
Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol (2011) 0.92
Assessment of risk for intra-abdominal adhesions at laparoscopy for urological tumors. J Urol (2002) 0.91
Why do phase III clinical trials in oncology fail so often? J Natl Cancer Inst (2012) 0.91
A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Mol Cancer Ther (2008) 0.91
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery (2013) 0.91
Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers. J Urol (2004) 0.90
Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res (2006) 0.90
Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab (2002) 0.90
Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp (2002) 0.89
Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res (2005) 0.89
Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res (2010) 0.89
Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res (2013) 0.89
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. Mol Cancer Ther (2004) 0.88
Oligomerization of p53 precedes its association with dynein and nuclear accumulation. Cell Cycle (2006) 0.88
Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol (2002) 0.87
Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. J Med Chem (2005) 0.87
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin Cancer Res (2003) 0.87
The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. Cancer Biol Ther (2003) 0.86
Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clin Cancer Res (2007) 0.86